AD/PD 2021 | Learnings from the PASADENA trial in Parkinson’s disease

Gennaro Pagano, MD, MSc, PhD, Expert Medical Director, Group Leader, Chair of Medical Directors Fellows at Roche Pharma Research and Early Development (pRED) and Researcher at King’s College London, discusses how the results from the PASADENA trial (NCT03100149) can inform future Parkinson’s disease clinical trials. Dr Pagano highlights the learnings from the PASADENA trial and how they were the basis for the next prasinezumab trial design. This interview took place during the AD/PD™ 2021 conference.